Abstract
Purpose
A large number of AML patients present with infection at the time of initial presentation in Indian settings. There is lack of published data on the proportion of patients with infection at initial presentation and its impact on induction mortality.
Methods
A retrospective audit of patients with newly diagnosed AML more than 14 years of age, who underwent standard induction chemotherapy between the periods of January 2011 to December 2018, was done. Infection at presentation if any was documented. Induction mortality was defined as death happening within 28 days of starting induction chemotherapy.
Results
Among a total of 315 cases of AML, 96 (30%) patients underwent induction chemotherapy with 7 + 3 regimen. Documented infection at baseline was present in 30 (31%) of patients. Another 10 patients had fever at the time of presentation but without any documented infection focus. Fifteen patients died within 4 weeks of induction amounting to induction mortality of 15.6%. Induction mortality was 28% among patients with infection at baseline compared with 7% without baseline infections (P = 0.01).
Conclusion
Around 40% of patients had fever at the time of presentation, and 31% had documented infections. Baseline infections led to increase in induction mortality. We would like to propose that infection at baseline is to be considered as one of the potential variables in the predictive scoring system for induction mortality in developing countries.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Kouchkovsky I, Abdul-Hay M (2016) ‘Acute myeloid leukemia: A comprehensive review and 2016 update.’ Blood Cancer J 6:e441
Rao AV (2016) Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. Hematology 2016:339–347. https://doi.org/10.1182/asheducation-2016.1.339
Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E (2014) Declining rates of treatment-related mortality in patients with newly diagnosed AML given “intense” induction regimens: a report from SWOG and MD Anderson. Leukemia 28:289–292. https://doi.org/10.1038/leu.2013.176
Bahl A, Sharma A, Raina V, Kumar L, Bakhshi S, Gupta R, Kumar R (2015) Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. Asia Pac J Clin Oncol 11:242–252. https://doi.org/10.1111/ajco.12333
Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, Lakshmi KM, Sitaram U, Abubacker FN, Abraham A, Viswabandya A, Srivastava VM, Srivastava A, Balasubramanian P, Mathews V (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170:110–117. https://doi.org/10.1111/bjh.13406
Murali NA, Ganesan P, Vijayakumar V et al (2016) Increasing incidence of multidrug-resistant Gram-negative septicaemia during induction therapy of acute myeloid leukaemia. J Hosp Infect 93:314–315. https://doi.org/10.1016/j.jhin.2016.04.012
Bhattacharya S, Goel G, Mukherjee S et al (2015) Epidemiology of antimicrobial resistance in an oncology center in eastern India. Infect Control Hosp Epidemiol 36:864–866. https://doi.org/10.1017/ice.2015.96
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 29:4417–4423. https://doi.org/10.1200/JCO.2011.35.7525
Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S (2010) Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 27:1037–1045. https://doi.org/10.1007/s12032-009-9330-9
Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, Kapil A (2012) Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol 29:1354–1360. https://doi.org/10.1007/s12032-011-9858-3
Atallah E, Cortes J, O’Brien S et al (2007) Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 110:3547–3551. https://doi.org/10.1182/blood-2007-06-095844
Nair R (2018) Impact of infection prior to the initiation of induction chemotheraphy on induction outcomes in patients with newly diagnosed acute leukemia in a tertiary centre hospital in India. EHA Library. 216103. https://library.ehaweb.org/eha/2018/stockholm/216103/ragesh.nair.impact.of.infection.prior.to.the.initiation.of.induction.html. Accessed 2 Oct 2019
Jacob S, Jacob SE, Suryanarayana BS, Dutta TK (2019) Clinical profile and short term outcome of adult patients with acute myeloid leukemia. Indian J Hematol Blood Transfus 35:431–436. https://doi.org/10.1007/s12288-018-1051-9
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340. https://doi.org/10.7326/0003-4819-64-2-328
Tiong IS, Reynolds J, Bradstock KF et al (2018) Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. Blood Cancer J 8:84
Aperis G, Alivanis P (2011) Posaconazole: a new antifungal weapon. Rev Recent Clin Trials 6:204–219. https://doi.org/10.2174/157488711796575595
Gafter-Gvili A, Fraser A, Paul M et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386. https://doi.org/10.1002/14651858.CD004386.pub3
Rüping MJGT, Vehreschild JJ, Cornely OA (2008) Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68:1941–1962
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 29:4417–4423. https://doi.org/10.1200/JCO.2011.35.7525
Buckley SA, Othus M, Estey EH, Walter RB (2015) The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. Blood Cancer J 5:e276
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Authors’ contribution
We, as authors, declare that the manuscript has been read and approved by all the authors, and that the requirements for authorship have been met, and that each author believes that the manuscript represents honest work. We as authors have full control of all primary data, and we agree to allow the journal to review the data if required.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pandian, J., Raghavan, V., Manuprasad, A. et al. Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world. Support Care Cancer 28, 5449–5454 (2020). https://doi.org/10.1007/s00520-020-05379-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-020-05379-z